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Background. Acute kidney injury (AKI) and metabolic acidosis are common in the intensive care unit. The effect of bicarbonate
administration on acid-base parameters is unclear in those receiving continuous venovenous hemofiltration (CVVH) andmechani-
cal ventilatory support.Methods. Metabolic and ventilatory parameters were prospectively examined in 19 ventilated subjects for up
to 96 hours followingCVVH initiation forAKI at an academic tertiary care center.Mixed linear regressionmodelingwas performed
to measure changes in pH, partial pressure of carbon dioxide (pCO
2
), serum bicarbonate, and base excess over time. Results.
During the 96-hour study period, pCO
2
levels remained stable overall (initial pCO
2
42.0 ± 14.6 versus end-study pCO
2
43.8 ±
16.1mmHg; 𝑃 = 0.13 for interaction with time), for those with initial pCO
2
≤40mmHg (31.3 ± 5.7 versus 35.0 ± 4.8; 𝑃 = 0.06)
and for those with initial pCO
2
>40mmHg (52.7 ± 12.8 versus 53.4 ± 19.2; 𝑃 = 0.57). pCO
2
decreased during the immediate
hours following CVVH initiation (42.0 ± 14.6 versus 37.3 ± 12.6mmHg), though this change was nonsignificant (𝑃 = 0.052).
Conclusions. We did not detect a significant increase in pCO
2
in response to the administration of bicarbonate via CVVH in a
ventilated population. Additional studies of larger populations are needed to confirm this finding.
1. Background
Acute kidney injury (AKI) in the critically ill is common and
associated with poor prognosis [1]. Metabolic acidosis occurs
frequently among those with AKI and is independently asso-
ciated with poor prognosis [2–4]. Metabolic acidosis is often
treated with sodium bicarbonate to mitigate complications
such as low vascular tone, depressed cardiac contractility, and
increased incidence of arrhythmias [5]. Despite this common
practice, there is minimal evidence showing a benefit to
bicarbonate administration, and there are several studies that
suggest harm. As a result, there is a lack of provider consensus
on best practice [6–11].
The potential harm of bicarbonate administration has
a plausible physiologic basis. First, delivery of bicarbonate
comes at the expense of an added sodium load that can con-
tribute to hypervolemia and further impair ventilation [12,
13]. In addition, bicarbonate may be dehydrated to peripheral
carbon dioxide. Peripheral carbon dioxide requires adequate
pulmonary function and gas exchange to be expired by the
respiratory system [14]. The effects of bicarbonate depend,
in part, on the nonbicarbonate buffering capacity of the
cellular environment, namely, the partial pressure of carbon
dioxide (pCO
2
) [15]. Several experimental and clinical studies
have shown that in certain situations the administration
of peripheral sodium bicarbonate can increase pCO
2
, thus
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underscoring the importance of adequate respiratory reserve
in patients with acidemia [16–18]. However, none of these
studieswere conducted in the setting of renal failure requiring
continuous renal replacement therapy.
Patients who require both renal replacement and ventila-
tor support highlight the complexities inherent in acidemia
and AKI. Renal replacement in the critically ill is often per-
formed via continuous venovenous hemofiltration (CVVH).
CVVHhas three distinct physiologic effects on acid-base bal-
ance: (1) removal of unmeasured anions through convection,
(2) addition of base (bicarbonate) by replacement infusion,
and (3) ultrafiltration, which can impact gas exchange [19,
20]. As a result, studies have shownmixed effects ofCVVHon
acid-base parameters [21–31]. However, there is a paucity of
evidence examining the effect of bicarbonate administration
via CVVH in a ventilated population. We therefore under-
took this study to analyze the impact of bicarbonate admin-
istration via CVVH on acid-base parameters and ventilation
status over the initial 96 hours of CVVH. CVVH is widely
used in the critically ill and in those with mixed respiratory
and metabolic acidosis. If there was a large negative impact
of bicarbonate administration in this setting, we might have
expected a change in practice pattern in this cohort. We
therefore hypothesized that bicarbonate administration via
CVVH would not increase pCO
2
levels.
2. Methods
2.1. Patient Population. We prospectively examined critically
ill patients in the intensive care unit (ICU) of Brigham and
Women’s Hospital, a 793-bed, academic tertiary care center
in Boston, Massachusetts, with eight specialized medical and
surgical ICUs. From August 2011 to February 2012, potential
subjects were identified by the nephrology ICU consult team
at the time of initiation of CVVH. The treating nephrol-
ogist determined the need for CVVH and its prescription
parameters including replacement fluid composition, rate,
and goal ultrafiltration. Inclusion criteria included age >18
years, presence of acute kidney injury requiring CVVH
therapy, and presence of mechanical ventilation at the start of
enrollment. Exclusion criteria included history of any renal
replacement therapy prior to ICU admission, presence of
chronic tracheostomy, history of traumatic or anoxic brain
injury, and history of end stage renal disease.
All data analyzed in this study were collected as part of
the routine clinical care for each subject. Through review
of medical records and CVVH and ICU flow sheets, a
member of the research team collected data prospectively
between time zero (start of CVVH) and hours 8, 16, 24,
36, 48, 60, 72, and 96 of receiving CVVH. Relevant data
included demographic information, vital signs, ventilator
settings, CVVH settings, comorbidities, active diagnoses, and
laboratory data.
2.2. Description of CVVH. CVVHwas performed via double-
lumen catheters using machines from NxStage Medical
(Lawrence,MA,USA)with prefilter fluid replacement. Target
replacement fluid rates were typically 20 to 30mL/kg/hour.
A 1 : 1 nursing ratio was employed for all patients on CVVH.
CVVHwas performed according to the local standard of care
with a preference for CVVH over intermittent dialysis for
patients with hemodynamic instability or for those receiving
vasopressor support. CVVH replacement fluids used during
the study period are described in Table 1.
2.3. Analysis of Laboratory Tests. Acid-base parameters and
partial pressures were calculated on arterial blood in hep-
arinized syringes whereas electrolytes, including bicarbonate
levels, were drawn from venous blood in tubes containing
EDTA. All blood samples were measured in the clinical
laboratory using standard clinical techniques.
2.4. Statistical Analysis. Baseline characteristics of subjects
overall and those stratified by partial arterial pressure of
carbon dioxide at time of continuous venovenous hemofil-
tration initiation were summarized as mean ± standard
deviation (SD) or number (percentage). Acid-base param-
eters and electrolytes are shown as mean ± SD, median
(25th, 75th percentile), and minimum-maximum values
based on normality diagnostics and clinical appropriateness.
Outcomes (change in serum pH, pCO
2
, HCO
3
, and base
excess) used a maximum-likelihood, mixed-effects repeated-
measures model (MMRM) with all longitudinal observa-
tions. Time was modeled as a continuous variable. Standard
diagnostics for normality were performed on baseline data,
outcomes, and outcome residuals, which supported normal-
ity assumptions and the validity of parametric regression
analysis. Univariate regression models were constructed to
evaluate the effect of potential confounders. As thiswas a pilot
study, the sample size was too small for multivariable model
adjustment. Sensitivity analyses were performed to evaluate
the effect of removing one subject who received peripheral
isotonic bicarbonate solution and one subject who received
citrate based replacement fluid. STATA version 13 (College
Station, Texas) was used for all statistical analysis. Two-tailed
𝑃 values <0.05 were considered statistically significant.
2.5. Ethics Statement. The institutional review board for
human subjects of the study hospital approved the study.
All clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki. All data
collected for this studywas done via review ofmedical record.
No direct contact wasmade betweenmembers of the research
team and any subject. The institutional review board waived
the need for informed consent.
3. Results
Demographic, clinical, and biochemical characteristics of
the study population are shown in Table 2. We studied 19
patients with a mean age of 57.5 years; 13 (68.4%) were male.
The most common admitting diagnoses were respiratory
failure/pneumonia (37%), heart failure/cardiogenic shock
(32%), and sepsis (26%). At the time of CVVH initiation, 74%
of subjects were vasopressor dependent, mean SOFA score
was 13.4 ± 3.5, and mean lactate was 4.1 ± 4.9mmol/L. One
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Table 1: Continuous venovenous hemofiltration replacement solution composition.
Bicarbonate Bicarbonate Bicarbonate Citrate
4K+/2.5Ca++ 2K+/0Ca++ 0K+/2.5Ca++
Sodium (mmol/L) 140 140 140 145
Potassium (mmol/L) 4.0 2.0 0 0.0
Magnesium (mEq/L) 1.5 1.0 1.5 1.5
Calcium (mmol/L) 2.5 0 2.5 0
Chloride (mmol/L) 113 111.5 109 105
Dextrose (mg/dL) 100 100 100 200
Citrate (mmol/L) 0 0 0 40
Bicarbonate (mmol/L) 32 32 32 0
Lactate (mmol/L) 3.0 3.0 3.0 0
subject (5%) was extubated at hour 48. Two subjects (11%)
died during the study period. All other subjects remained on
CVVH until the end of the study period.
The mean pH at CVVH initiation was 7.32 ± 0.12. Nine
subjects (47%) had an initial pCO
2
≤40mmHg (mean initial
pH 7.40 ± 0.06), nine subjects (47%) had an initial pCO
2
>40mmHg (mean initial pH 7.24 ± 0.12), and one subject did
not have an initial blood gas available at the time of CVVH
initiation. Mean blood urea nitrogen (BUN) decreased from
68.4± 35.0mg/dL at CVVH initiation to 29.4± 14.2 at the end
of the study period (𝑃 < 0.001). Mean creatinine decreased
from 3.9 ± 1.2mg/dL at CVVH initiation to 1.7 ± 0.7mg/dL at
the end of the study period (𝑃 < 0.001; Table 3).
Bicarbonate based replacement solution (32mEq/L) was
used in 18 of 19 subjects (95%). The remaining subject
received citrate based replacement solution (citrate concen-
tration 40mEq/L). Across the entire study period, mean
blood flow rate was 238 ± 33mL/min, mean replacement
solution flow rate was 2214 ± 484mL/h, and mean ultrafil-
tration rate was 45 ± 62mL/h (Table 4).
The majority of subjects were supported on assist control
or pressure control ventilation at the time of enrollment
(90%), but this decreased to 41% by hour 96. Across the
96-hour study duration, there were no significant changes
in PEEP (𝑃 = 0.25), achieved tidal volume (𝑃 = 0.95),
ventilator-set respiratory rate (𝑃 = 0.15), subject respiratory
rate (𝑃 = 0.60), or FIO
2
(𝑃 = 0.10; Table 5).
Values of acid-base parameters and electrolytes across
each time point are detailed in Table 3. During the 96-hour
study period, pCO
2
levels remained stable overall (initial
pCO
2
42.0 ± 14.6 versus end-study pCO
2
43.8 ± 16.1mmHg;
𝑃 = 0.13 for interaction with time). Neither the low initial
pCO
2
subgroup (≤40mmHg) nor the high initial pCO
2
sub-
group (>40mmHg) had a significant change in pCO
2
during
the 96-hour study period (31.3 ± 5.7 versus 35.0 ± 4.8, 𝑃 =
0.06, and 52.7 ± 12.8 versus 53.4 ± 19.2, 𝑃 = 0.57, resp.). There
was a decrease in pCO
2
during the immediate hours following
CVVH initiation (42.0 ± 14.6mmHg at hour 0 versus 37.3 ±
12.6mmHg at hour 8), though this change was nonsignificant
(𝑃 = 0.052). Results were qualitatively similar in separate
secondary analyses excluding the subject who received citrate
replacement solution and the subject who received three liters
of additional isotonic sodium bicarbonate intravenous fluid.
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Figure 1: Changes in mean partial arterial pressure of carbon
dioxide (pCO
2
) and pH over time.
Across all subjects, there was a nonsignificant (𝑃 = 0.12)
increase in pH for the 96-hour study duration (Figure 1). pH
increased from 7.32 ± 0.12 at hour 0 to 7.37 ± 0.10 at hour 8
(𝑃 = 0.01). For serum HCO
3
levels, there was a significant
(𝑃 = 0.003) increase across the 96-hour study period (see
Supplementary Figure in the Supplementary Material avail-
able online at http://dx.doi.org/10.1155/2015/901590). There
was no significant change in HCO
3
between hour 0 and hour
8 (𝑃 = 0.57). For base excess, there was a significant (𝑃 =
0.005) increase across the 96-hour study period.Therewas no
significant change in base excess between hour 0 and hour 8
(𝑃 = 0.13).
4. Discussion
We studied the effects of large volume bicarbonate infusion
via CVVH in a ventilated cohort and found that there was
no significant change in pCO
2
in response to bicarbonate
administration across a 96-hour period of observation. Dur-
ing the first 8 hours of CVVH use, there was a significant
improvement in acidemia and a trend toward a decrease
in pCO
2
. This nonsignificant decrease in pCO
2
disappeared
over the course of 96 hours. While this was observed in
a small sample, it provides preliminary data for hypothesis
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Table 2: Baseline patient characteristics by partial arterial pressure of carbon dioxide at time of continuous venovenous hemofiltration
initiationa.
Patients 𝑝CO2 ≤ 40mmHg 𝑝CO2 > 40mmHg
(𝑛 = 19)b (𝑛 = 9) (𝑛 = 9)
Age 57.5 ± 15.4 61.8 ± 17.3 55.2 ± 13.0
Male 13 (68.4) 6 (66.7) 7 (77.8)
ICU type
Medical 7 (36.8) 3 (33.3) 3 (33.3)
Surgicalc 7 (36.8) 4 (44.5) 3 (33.3)
Cardiac 5 (26.2) 2 (22.2) 3 (33.3)
ICU admission diagnosis
Sepsis 5 (26.3) 2 (22.2) 2 (22.2)
Heart failure/cardiogenic shock 6 (31.6) 1 (11.1) 5 (55.6)
Respiratory failure/pneumonia 7 (36.8) 5 (55.6) 2 (22.2)
Other causesd 1 (5.3) 1 (11.1) 0
Preexisting comorbid condition
Hypertension 10 (52.6) 5 (55.6) 5 (55.6)
Coronary artery disease 5 (26.3) 1 (11.1) 4 (44.4)
Chronic kidney diseasee 7 (36.8) 2 (22.2) 5 (55.6)
Diabetes mellitus 10 (52.6) 2 (22.2) 7 (77.8)
Liver disease 1 (5.3) 0 0
COPD 6 (31.5) 3 (33.3) 2 (22.2)
Cancer 7 (36.8) 3 (33.3) 4 (44.4)
Systolic blood pressure (mmHg) 95.6 ± 16.2 100.8 ± 14.4 89.3 ± 17.3
Vasopressor dependency 14 (73.7) 6 (66.7) 8 (88.9)
Urine output (mL)f 14.6 (17.1) 12.6 ± 17.4 17.2 ± 18.4
SOFA scoreg 13.4 ± 3.5 12.8 ± 4.1 14.0 ± 2.7
pHg 7.32 ± 0.12 7.40 ± 0.06 7.24 ± 0.12
Creatinine (mg/dL) 3.9 ± 1.2 3.8 ± 1.0 3.8 ± 1.3
Blood urea nitrogen (mg/dL) 68.4 ± 35.8 57.2 ± 29.4 72.1 ± 36.3
Potassium (mmol/L) 4.9 ± 1.0 4.5 ± 1.2 5.2 ± 0.8
Lactate (mmol/L)h 4.1 ± 4.9 4.7 ± 5.6 3.4 ± 4.2
White blood cell count (K/𝜇L) 15.7 ± 6.6 15.6 ± 5.5 17.1 ± 7.1
Platelets (K/𝜇L) 135 ± 111 120 ± 90 163 ± 130
Mortality within 7 days of CVVH initiation 2 (10.5) 0 2 (22.2)
aValues presented as mean ± standard deviation or 𝑛 (%).
b1 of 19 patients did not have a starting arterial blood gas.
cIncluding surgical, cardiothoracic, and cardiac surgery ICUs.
dRetroperitoneal bleed.
eIncluding 1 end stage renal disease patient on dialysis.
fUrine output in 1-hour period prior to starting CVVH.
g
𝑁 = 18.
h
𝑁 = 15 for all patients,𝑁 = 8 for 𝑝CO2 ≤ 40mmHg, and𝑁 = 7 for 𝑝CO2 > 40mmHg.
ICU: intensive care unit; CVVH: continuous venovenous hemofiltration; COPD: chronic obstructive pulmonary disease, K: 1000, and 𝑝CO2: partial arterial
pressure of carbon dioxide.
generation and supports further study of a clinically relevant
impact in acid-base handling in the ICU.
The impact of CVVH on acid-base parameters is impor-
tant. Like in prior work, our study relies on pCO
2
as a
clinical marker of total tissue carbon dioxide content, which
is the ultimate driver of hypercapnia. While the delivery of a
buffer (usually bicarbonate) during CVVH is relied upon to
treat metabolic acidosis [19], clinicians are often concerned
about a potential compensatory increase in pCO
2
, especially
in patients with limited respiratory reserve. However, prior
analyses examining the effect of renal replacement on acid-
base parameters have had inconsistent results across varied
clinical scenarios. Rocktäschel et al. published a study of
40 subjects receiving CVVH and reported increases in pH,
pCO
2
, and bicarbonate levels over 3 daily lab measurements
[21]. Compared to this study, our study provides more
granularity with additional time points and an extended
follow-up period. Our results do not confirm their findings.
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Table 3: Acid-base parameters and electrolytesa.
Hour 0 Hour 8 Hour 16 Hour 24 Hour 36 Hour 48 Hour 60 Hour 72 Hour 96
pH 7.32 ± 0.12 7.37 ± 0.08 7.37 ± 0.10 7.37 ± 0.08 7.39 ± 0.09 7.37 ± 0.08 7.38 ± 0.07 7.38 ± 0.07 7.37 ± 0.11
(n = 18) (n = 18) (n = 18) (n = 18) (n = 19) (n = 17) (n = 18) (n = 18) (n = 17)
𝑝CO2 (mmHg)
42.0 ± 14.6 37.3 ± 12.6 38.1 ± 9.7 39.9 ± 10.3 40.1 ± 11.6 39.4 ± 11.6 40.6 ± 10.3 42.2 ± 10.2 43.8 ± 16.1
(n = 18) (n = 18) (n = 18) (n = 18) (n = 19) (n = 17) (n = 18) (n = 18) (n = 17)
HCO3 (mmol/L)
b 19.8 ± 5.1 20.1 ± 5.1 19.7 ± 4.2 22.3 ± 3.9 22.8 ± 3.7 23.1 ± 3.2 22.8 ± 3.5 23.3 ± 2.4 23.2 ± 3.8
(n = 19) (n = 18) (n = 18) (n = 18) (n = 19) (n = 17) (n = 18) (n = 16) (n = 16)
Base excess (mmol/L) −5.2 ± 6.5 −4.2 ± 5.4 −3.9 ± 5.4 −3.3 ± 3.6 −2.2 ± 3.0 −2.3 ± 2.7 −1.8 ± 3.3 −1.2 ± 2.6 −1.4 ± 3.3
(n = 18) (n = 18) (n = 18) (n = 18) (n = 19) (n = 17) (n = 18) (n = 18) (n = 17)
Sodium (mmol/L) 132.7 ± 6.5 132.8 ± 5.1 132.5 ± 5.6 132.5 ± 5.9 132.1 ± 3.9 132.1 ± 3.9 132.1 ± 4.2 132.4 ± 4.1 131.1 ± 3.8
(n = 19) (n = 18) (n = 18) (n = 18) (n = 19) (n = 17) (n = 18) (n = 16) (n = 16)
Potassium (mmol/L) 4.9 ± 1.0 4.6 ± 0.8 4.6 ± 0.7 4.6 ± 0.7 4.5 ± 0.6 4.5 ± 0.8 4.4 ± 0.4 4.3 ± 0.5 4.5 ± 0.5
(n = 19) (n = 19) (n = 18) (n = 19) (n = 19) (n = 19) (n = 18) (n = 17) (n = 16)
Chloride (mmol/L) 96.4 ± 6.2 97.2 ± 5.7 97.4 ± 4.5 97.3 ± 5.4 98.5 ± 4.6 99.2 ± 3.5 98.2 ± 4.1 99.3 ± 3.7 98.8 ± 4.0
(n = 19) (n = 18) (n = 18) (n = 18) (n = 19) (n = 17) (n = 18) (n = 16) (n = 16)
Ionized calcium (mg/dL) 1.03 ± 0.1 1.08 ± 0.3 1.05 ± 0.1 1.04 ± 0.1 1.03 ± 0.1 1.08 ± 0.1 1.09 ± 0.1 1.11 ± 0.1 1.11 ± 0.1
(n = 19) (n = 16) (n = 17) (n = 19) (n = 18) (n = 16) (n = 18) (n = 16) (n = 15)
BUN (mg/dL) 68.4 ± 35.8 60.2 ± 33.2 51.8 ± 27.1 45.4 ± 22.5 40.1 ± 20.2 37.5 ± 18.9 34.1 ± 16.4 30.5 ± 15.2 29.4 ± 14.6
(n = 19) (n = 18) (n = 18) (n = 18) (n = 19) (n = 17) (n = 18) (n = 16) (n = 16)
Creatinine (mg/dL) 3.9 ± 1.2 3.5 ± 1.2 3.1 ± 1.1 2.8 ± 1.0 2.4 ± 1.0 2.3 ± 0.8 2.0 ± 0.7 2.0 ± 0.7 1.7 ± 0.7
(n = 19) (n = 18) (n = 18) (n = 18) (n = 19) (n = 17) (n = 18) (n = 16) (n = 16)
aValues presented as mean ± standard deviation.
bDrawn from venous chemistry panel.
𝑝CO2: partial arterial pressure of carbon dioxide, HCO3: bicarbonate, and BUN: blood urea nitrogen.
Table 4: Continuous venovenous hemofiltration prescription characteristics.
All subjects
(𝑛 = 19)
Bicarbonate
4K+/2.5Ca++
(𝑛 = 10)
Bicarbonate
2K+/0Ca++
(𝑛 = 5)
Bicarbonate
0K+/2.5Ca++
(𝑛 = 3)
Citrate
(𝑛 = 1)
Blood flow rate (mL/min)
Mean ± SD 238 ± 33 238 ± 34 244 ± 17 247 ± 11 175 ± 46
Median [25th, 75th] 250 [250, 250] 250 [250, 250] 250 [250, 250] 250 [250, 250] 150 [150, 200]
(min, max) (150, 250) (150, 250) (200, 250) (200, 250) (150, 250)
Solution flow rate (mL/h)
Mean ± SD 2214 ± 484 2158 ± 462 2220 ± 527 2563 ± 453 2050 ± 256
Median [25th, 75th] 2000 [2000, 2400] 2000 [2000, 2400] 2000 [2000, 2400] 2500 [2000, 3000] 2000 [2000, 2200]
(min, max) (2000, 3200) (2000, 3200) (2000, 3000) (2000, 3000) (1600, 2400)
Ultrafiltration rate (mL/h)
Mean ± SD 45 ± 62 47 ± 63 39 ± 51 45 ± 53 50 ± 53
Median [25th, 75th] 0 [0, 100] 10 [0, 100] 0 [0, 100] 0 [0, 50] 50 [0, 100]
(min, max) (0, 250) (0, 250) (0, 150) (0, 250) (0, 100)
Rates reflect average values over the course of the 96-hour study duration.𝑁 represents the number of subjects on a given solution prescription at the time of
CVVH initiation.
This may be due to differences in sample characteristics
(the ventilation status of their cohort was not reported) and
delivery of CVVH (the buffer used for CVVH in their study
was lactate, rather than bicarbonate) [21]. Tan et al. compared
lactate and bicarbonate replacement solution for CVVH in
eight patients over 120 minutes and did not show differences
in any acid-base parameters [30]. This may not have been a
long enough observation period to detect significant changes.
Neither of these two papers reflects current clinical practice,
as the use of lactate as a buffer in CVVH replacement fluid
has been largely replaced by bicarbonate. Symreng et al.
examined seven nonventilated subjects on high efficiency
dialysis over 6 hours and showed an increase in tidal volume
but not pCO
2
. These findings lead to the conclusion that a
healthy ventilatory response is required to excrete the pCO
2
generated by infusion of a buffer [29]. It is hard to apply
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Table 5: Ventilator settings.
Hour 0 Hour 8 Hour 16 Hour 24 Hour 36 Hour 48 Hour 60 Hour 72 Hour 96
(𝑁 = 19) (𝑁 = 19) (𝑁 = 19) (𝑁 = 19) (𝑁 = 19) (𝑁 = 17) (𝑁 = 17) (𝑁 = 17) (𝑁 = 16)
Mode
AC or PC 17 (89.5%) 16 (84.2) 15 (78.9) 15 (78.9) 14 (73.7) 12 (70.6) 12 (70.6) 10 (58.8) 7 (41.2)
PS 2 (10.5%) 2 (10.5) 3 (15.8) 3 (15.8) 4 (21.0) 4 (21.0) 4 (21.0) 6 (35.3) 8 (47.1)
Oscillatora 0 1 (5.3) 1 (5.3) 1 (5.3) 1 (5.3) 1 (5.3) 1 (5.3) 1 (5.9) 1 (5.9)
PEEP (cm H2O) 8.0 ± 3.5 9.0 ± 6.0 9.0 ± 6.0 9.3 ± 6.0 10.0 ± 7.4 10.2 ± 7.7 10.7 ± 7.9 10.1 ± 7.7 9.1 ± 7.3
Achieved tidal
volume (mL) 520 ± 128
519 ± 122 518 ± 130 520 ± 133 519 ± 122 506.1 ± 134.1 503.5 ± 156.0 495.4 ± 142.4 540.3 ± 162.5
(𝑛 = 18) (𝑛 = 18) (𝑛 = 18) (𝑛 = 18) (𝑛 = 16) (𝑛 = 16) (𝑛 = 16) (𝑛 = 15)
Ventilator RR
(/minute)
22.0 ± 7.5 23.0 ± 8.3 23.0 ± 8.8 21.9 ± 8.2 22.2 ± 7.9 22.9 ± 7.6 22.3 ± 8.0 22.5 ± 8.1 20.7 ± 8.9
(𝑛 = 18)
Subject RR (/minute) 23.5 ± 8.8 23.5 ± 8.8 23.5 ± 8.6 22.7 ± 8.4 23.5 ± 7.6 24.8 ± 8.3 23.8 ± 9.1 24.3 ± 7.9 22.8 ± 9.6
FIO2 (%) 62.4 ± 24.5 58.7 ± 20.5 53.9 ± 20.0 53.4 ± 21.7 55.5 ± 23.1 54.2 ± 24.6 56.5 ± 24.5 53.8 ± 22.1 53.8 ± 22.1
aHigh frequency oscillator ventilator.
AC: assist control; PC: pressure control; PS: pressure support; PEEP: positive end expiratory pressure; RR: respiratory rate; FIO2: fraction of inspired oxygen.
these results to critically ill patients given this was not a study
performed in the ICU setting.
Our study is the first to examine the acid-base parameters
in a cohort simultaneously receiving CVVH and uniformly
receiving mechanical ventilatory support. This sample was
selected to examine the effects of high-rate delivery of bicar-
bonate or bicarbonate equivalents (citrate) in patients with
impaired respiratory reserve. This cohort was at increased
risk for hypercarbia due to the conversion of bicarbonate into
carbon dioxide. Given the lack of significant increase in pCO
2
across the initial 96 hours of CVVH, this suggests that the
effect of bicarbonate on pCO
2
may not be substantial even
in a critically ill, ventilated population. Although our sample
size was small, a subgroup analysis of individuals with an
initial pCO
2
above 40mmHg was reassuring. No significant
change in pCO
2
was seen in this group with the most
impaired gas exchange.There were only 3 patients with initial
pCO
2
≥65mmHg, so it is not clear if these results would
apply to those with extreme hypercarbia. Furthermore, there
were no patients in this sample undergoing simultaneous
extracorporeal carbon dioxide removal (e.g., ECMOdevices).
Those with such extreme physiology warrant further study,
as the use of both circuits in series for patients who have
concurrent severe metabolic and respiratory acidosis is not
clearly defined. Nevertheless, this further suggests that the
physiologic effects of bicarbonate are tolerable even in those
with concurrent respiratory acidosis.
It was surprising that during the first eight-hour interval
there was an initial drop in pCO
2
in response to starting
CVVH that approached statistical significance. This is oppo-
site of the expected physiologic impact of bicarbonate admin-
istration on pCO
2
[16–18]. Several factors could account for
this initial decrease, including transcellular shifts of pCO
2
,
concurrent ultrafiltration (which could result in improved gas
exchange given a mean 45mL/hour ultrafiltration rate for all
subjects), or other unmeasured properties of this population.
Nevertheless, the observation that the pCO
2
levels decreased
initially is reassuring and suggests that even in this population
there is likely to be sufficient native or assisted ventilatory
reserve to compensate appropriately for changes in pCO
2
generation following bicarbonate administration.
This sample did not include patients who received periph-
eral sodium bicarbonate without CVVH support. These
results should not be extrapolated to patients not receiving
renal replacement. While the same principles might apply
to bicarbonate/carbon dioxide handling in all patients in
the ICU regardless of renal replacement status, there are
additional physiologic effects of CVVH, such as fluid removal
via ultrafiltration and clearance of other toxins and inflam-
matory cytokines that may influence acid-base management.
In addition, the gradual infusion of bicarbonate via CVVH
(a mean change of only 3.4mEq/dL serum HCO
3
over
the 96-hour study period) may permit time for respiratory
compensation, which may be better tolerated than bolus
delivery of ampules of sodium bicarbonate. However, this is
speculative, and further study of patients not requiring renal
replacement therapy is needed.
Our findings should be understood within the context
of several limitations of the study design. The sample size
was small, which limited the ability to control for multiple
confounders in regression analysis and also limited power
to detect small changes in pCO
2
. Confirmation in a larger
cohort is needed, but pCO
2
actually decreased during the first
8 hours, suggesting that the small size is of the cohort is an
unlikely explanation for the failure to demonstrate an increas-
ing trend in pCO
2
during bicarbonate CVVH. Furthermore,
meticulous measurements across standardized time intervals
allowed us to characterize acid-base parameters in greater
detail than previous analyses. Additionally, outcomes and
observations were all physiologic measurements. This study
was not designed or powered to look at the impact on
clinical outcomes such as time on the ventilator, time on
CVVH, or mortality, although those outcomes are clearly of
great interest. We studied a cohort with a greater severity
of illness than the average ICU patient [32]. Thus, our
results may not be generalizable to less severely ill patients,
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although the group we analyzed would be more likely to
exhibit consequences of bicarbonate-induced hypercarbia
than less severely ill patients. Additionally, there were not
enough subjects with pCO
2
>65mmHg to draw definitive
conclusions about those with severe hypercarbia. Finally, the
amount of CVVH downtime was not recorded as part of
the routine clinical care of these subjects. This factor could
have altered bicarbonate delivery. However, the significant
decrease observed in BUN and Cr suggests that downtime
was minimal over the 96-hour observation period.
We conclude that, in this sample, there was no significant
increase in pCO
2
in response to the administration of
large volumes of bicarbonate via CVVH in this ventilated
population. This finding should be confirmed in a larger
study that can be powered to adjust for multiple potential
confounders of the association. Our results suggest that a
clinically relevant increase in pCO
2
is not an inevitable
complication of the administration of bicarbonate through
CVVH in ventilated patients.There remains a need for future
studies to characterize the complex acid-base interactions
in patients receiving CVVH, peripheral bicarbonate, and
ventilator support.
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